KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on Sales

Recursion Pharmaceuticals (RXRX) Return on Sales (2020 - 2025)

Recursion Pharmaceuticals (RXRX) has disclosed Return on Sales for 6 consecutive years, with 3.04% as the latest value for Q4 2025.

  • For the quarter ending Q4 2025, Return on Sales rose 3631.0% year-over-year to 3.04%, compared with a TTM value of 8.63% through Dec 2025, down 75.0%, and an annual FY2025 reading of 8.63%, down 75.0% over the prior year.
  • Return on Sales was 3.04% for Q4 2025 at Recursion Pharmaceuticals, up from 31.35% in the prior quarter.
  • Across five years, Return on Sales topped out at 3.04% in Q4 2025 and bottomed at 39.35% in Q4 2024.
  • Average Return on Sales over 5 years is 12.17%, with a median of 8.73% recorded in 2022.
  • The sharpest move saw Return on Sales surged 29382bps in 2021, then crashed -3082bps in 2024.
  • Year by year, Return on Sales stood at 25.65% in 2021, then skyrocketed by 83bps to 4.46% in 2022, then crashed by -91bps to 8.54% in 2023, then crashed by -361bps to 39.35% in 2024, then soared by 92bps to 3.04% in 2025.
  • Business Quant data shows Return on Sales for RXRX at 3.04% in Q4 2025, 31.35% in Q3 2025, and 8.94% in Q2 2025.